DHRS13

Summary

DHRS13 (dehydrogenase/reductase 13, HGNC:28326) is a protein-coding gene on chromosome 17q11.2, encoding Dehydrogenase/reductase SDR family member 13 (Q6UX07). Putative oxidoreductase.

Predicted to enable oxidoreductase activity. Located in membrane.

Source: NCBI Gene 147015 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_144683

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28326
Approved symbol	DHRS13
Name	dehydrogenase/reductase 13
Location	17q11.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC23280, SDR7C5
Ensembl gene	ENSG00000167536
Ensembl biotype	protein_coding
OMIM	616157
Entrez	147015

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000378895, ENST00000394901, ENST00000426464, ENST00000581759, ENST00000581974, ENST00000913592

RefSeq mRNA: 1 — MANE Select: NM_144683 NM_144683

CCDS: CCDS11246

Canonical transcript exons

ENST00000378895 — 5 exons

Exon	Start	End
ENSE00000866373	28900990	28901301
ENSE00001052792	28901493	28901616
ENSE00001479180	28902583	28902701
ENSE00001479182	28902818	28903079
ENSE00001782732	28897781	28898892

Expression profiles

Bgee: expression breadth ubiquitous, 135 present calls, max score 95.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.7110 / max 265.6615, expressed in 1347 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165096	2.8680	1057
165097	2.6036	1032
165095	0.1365	37
165094	0.1029	26

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.06	gold quality
blood	UBERON:0000178	93.52	gold quality
cerebellum	UBERON:0002037	87.99	gold quality
cerebellar hemisphere	UBERON:0002245	87.96	gold quality
cerebellar cortex	UBERON:0002129	87.93	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.86	gold quality
bone marrow	UBERON:0002371	84.68	gold quality
prostate gland	UBERON:0002367	84.37	gold quality
cerebellar vermis	UBERON:0004720	83.08	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.75	gold quality
spleen	UBERON:0002106	82.39	gold quality
cortical plate	UBERON:0005343	82.28	gold quality
granulocyte	CL:0000094	81.60	gold quality
mucosa of transverse colon	UBERON:0004991	79.96	gold quality
ventricular zone	UBERON:0003053	79.35	gold quality
hypothalamus	UBERON:0001898	79.33	gold quality
saliva-secreting gland	UBERON:0001044	79.22	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.97	gold quality
bone marrow cell	CL:0002092	78.97	gold quality
minor salivary gland	UBERON:0001830	78.94	gold quality
thymus	UBERON:0002370	78.72	silver quality
adult mammalian kidney	UBERON:0000082	78.68	gold quality
vermiform appendix	UBERON:0001154	78.24	gold quality
esophagus mucosa	UBERON:0002469	78.22	gold quality
right lobe of liver	UBERON:0001114	77.53	gold quality
ganglionic eminence	UBERON:0004023	77.26	gold quality
cortex of kidney	UBERON:0001225	77.17	gold quality
lymph node	UBERON:0000029	76.99	gold quality
left adrenal gland	UBERON:0001234	76.91	gold quality
metanephros cortex	UBERON:0010533	76.91	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.36

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting DHRS13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-6733-3P	99.54	67.80	1281
HSA-MIR-5571-5P	99.49	66.99	1764
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-1227-5P	98.65	65.32	1549
HSA-MIR-561-5P	98.25	68.13	1365
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-7112-3P	97.67	68.77	948
HSA-MIR-4639-3P	97.54	67.12	787
HSA-MIR-3173-5P	97.35	65.82	1282
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-383-5P	96.86	67.55	820
HSA-MIR-668-3P	96.18	65.80	673
HSA-MIR-6835-5P	95.81	64.27	500

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	dhrs13a.1	ENSDARG00000026322
danio_rerio	dhrs13b.1	ENSDARG00000031814
danio_rerio	dhrs13a.3	ENSDARG00000041137
danio_rerio	dhrs13l1	ENSDARG00000098746
danio_rerio	dhrs13a.2	ENSDARG00000111240
mus_musculus	Dhrs13	ENSMUSG00000020834
rattus_norvegicus	Dhrs13	ENSRNOG00000072884
caenorhabditis_elegans		WBGENE00000971
caenorhabditis_elegans		WBGENE00000972
caenorhabditis_elegans		WBGENE00010762
caenorhabditis_elegans		WBGENE00017082
caenorhabditis_elegans		WBGENE00017131
caenorhabditis_elegans		WBGENE00017971

Paralogs (4): KDSR (ENSG00000119537), RDH13 (ENSG00000160439), DHRSX (ENSG00000169084), RDH14 (ENSG00000240857)

Protein

Protein identifiers

Dehydrogenase/reductase SDR family member 13 — Q6UX07 (reviewed: Q6UX07)

Alternative names: Short chain dehydrogenase/reductase family 7C member 5

All UniProt accessions (1): Q6UX07

UniProt curated annotations — full annotation on UniProt →

Function. Putative oxidoreductase.

Subcellular location. Secreted.

Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6UX07-1	1	yes
Q6UX07-2	2
Q6UX07-3	3

RefSeq proteins (1): NP_653284* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002347	SDR_fam	Family
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily

Pfam: PF00106

UniProt features (17 total): binding site 6, compositionally biased region 3, splice variant 2, sequence variant 2, signal peptide 1, chain 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UX07-F1	82.78	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 197 (proton acceptor)

Ligand- & substrate-binding residues (6): 197; 201; 232; 46; 48; 170

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): chr17q11, LIAO_METASTASIS, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, BASAKI_YBX1_TARGETS_DN, LIAO_HAVE_SOX4_BINDING_SITES, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, KRIEG_HYPOXIA_NOT_VIA_KDM3A, E2F3_UP.V1_UP, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP, ATF6_TARGET_GENES, KAT5_TARGET_GENES, NAB2_TARGET_GENES, PAX8_TARGET_GENES, SFMBT1_TARGET_GENES, SKIL_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (2): oxidoreductase activity (GO:0016491), protein binding (GO:0005515)

GO Cellular Component (2): extracellular region (GO:0005576), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
catalytic activity	1
binding	1

Protein interactions and networks

STRING

3047 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DHRS13	PRSS35	Q8N3Z0	564
DHRS13	ADAMTS9	Q9P2N4	558
DHRS13	RGS17	Q9UGC6	506
DHRS13	KCNQ3	O43525	485
DHRS13	FAM131A	Q6UXB0	478
DHRS13	GLIPR1L2	Q4G1C9	466
DHRS13	SIGLEC15	Q6ZMC9	461
DHRS13	DCLK1	O15075	437
DHRS13	HIBADH	P31937	434
DHRS13	EPCIP	Q9NYP8	418
DHRS13	GCSAML	Q5JQS6	413
DHRS13	KLHDC8B	Q8IXV7	402
DHRS13	CLDND2	Q8NHS1	399
DHRS13	GAL3ST4	Q96RP7	397
DHRS13	LRRN2	O75325	397

IntAct

39 interactions, top by confidence:

A	B	Type	Score
RANBP6	SLC27A2	psi-mi:“MI:0914”(association)	0.640
DHRS13	KIFBP	psi-mi:“MI:0915”(physical association)	0.640
TNFSF8	TOR1B	psi-mi:“MI:0914”(association)	0.640
SLC1A1	AGPAT2	psi-mi:“MI:0914”(association)	0.640
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
LDLRAD1	ADAM10	psi-mi:“MI:0914”(association)	0.530
SLC31A1	PRORP	psi-mi:“MI:0914”(association)	0.530
TNFSF8	NME4	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
ATG16L1		psi-mi:“MI:0914”(association)	0.350
KCNA2	TMEM129	psi-mi:“MI:0914”(association)	0.350
TTMP	TMEM223	psi-mi:“MI:0914”(association)	0.350
RAMP2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
LRRC55	TMEM120B	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
MFSD4A	UBXN8	psi-mi:“MI:0914”(association)	0.350
SYP	HAS3	psi-mi:“MI:0914”(association)	0.350
DHRS13	HSPA8	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
CHIA	SLC25A16	psi-mi:“MI:0914”(association)	0.350
GPR182	TMEM120B	psi-mi:“MI:0914”(association)	0.350
HAUS7	RFPL4A	psi-mi:“MI:0914”(association)	0.350
SETD6	GFPT2	psi-mi:“MI:0914”(association)	0.350
SYP	TMEM223	psi-mi:“MI:0914”(association)	0.350
TMED5	DGAT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (54): KIAA1279 (Affinity Capture-MS), DHRS13 (Affinity Capture-MS), DHRS13 (Affinity Capture-MS), KIAA1279 (Affinity Capture-MS), DHRS13 (Affinity Capture-MS), DHRS13 (Affinity Capture-MS), DHRS13 (Affinity Capture-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS), DHRS13 (Proximity Label-MS)

ESM2 similar proteins: A0A061IR73, A2ARS0, A6NE52, A6QPE7, A8MYJ7, A8VU90, C9JTQ0, E1BD59, E5RJM6, O08672, P54777, Q08353, Q0P5G1, Q0V8J4, Q13470, Q13608, Q15653, Q28616, Q2TB02, Q3SWY4, Q3UYR4, Q53GL7, Q58EX7, Q5IJ48, Q5JR98, Q60778, Q62893, Q6EMK4, Q6F5E8, Q6MG64, Q6P7C4, Q6UX07, Q6ZMH5, Q6ZVH7, Q6ZVZ8, Q7RTR2, Q8CDY7, Q8CIE4, Q8K592, Q8NI38

Diamond homologs: A0A017SEY2, A0A023I4F1, A0A0C6DRT7, A0A1B7YCL6, A0A2P1DP77, A0A345BJN5, A0A482ND39, A0A4P8DJW5, A0A5B8YU33, A0AAW1NHX6, A2RVM0, B2X050, B6H062, B6HLP6, B8M9L2, C8V3Y7, D7UQ42, F4JJR8, G1XTZ5, G3Y422, G4MVZ5, G9N4A1, G9N4A6, I1S2J3, O48741, O75828, O80333, P00335, P0DXW2, P15428, P16232, P19992, P21218, P28845, P42317, P50199, P50203, P51975, P70684, P9WEF8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 53 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SLC-mediated transmembrane transport	6	10.8×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

695 predictions. Top by Δscore:

Variant	Effect	Δscore
17:28900985:CTCA:C	donor_loss	1.0000
17:28901487:CCTCA:C	donor_loss	1.0000
17:28901488:CTCAC:C	donor_loss	1.0000
17:28901489:TCAC:T	donor_loss	1.0000
17:28901490:CAC:C	donor_loss	1.0000
17:28901492:CCGG:C	donor_gain	1.0000
17:28901612:CTCTC:C	acceptor_gain	1.0000
17:28902579:TCACC:T	donor_loss	1.0000
17:28902580:CA:C	donor_loss	1.0000
17:28902710:C:CT	acceptor_gain	1.0000
17:28902816:AC:A	donor_gain	1.0000
17:28902817:CC:C	donor_gain	1.0000
17:28898889:GGCCC:G	acceptor_loss	0.9900
17:28898890:GCCCT:G	acceptor_loss	0.9900
17:28898891:CC:C	acceptor_gain	0.9900
17:28898892:CCTG:C	acceptor_gain	0.9900
17:28898892:CCTGT:C	acceptor_loss	0.9900
17:28898894:T:G	acceptor_loss	0.9900
17:28900988:A:AC	donor_gain	0.9900
17:28900989:C:CC	donor_gain	0.9900
17:28901491:A:AC	donor_gain	0.9900
17:28901492:C:CC	donor_gain	0.9900
17:28901614:CTC:C	acceptor_gain	0.9900
17:28901615:TC:T	acceptor_gain	0.9900
17:28901615:TCC:T	acceptor_loss	0.9900
17:28901616:CC:C	acceptor_gain	0.9900
17:28901617:C:A	acceptor_loss	0.9900
17:28901617:C:CC	acceptor_gain	0.9900
17:28901618:T:A	acceptor_loss	0.9900
17:28901619:G:GC	acceptor_gain	0.9900

AlphaMissense

2388 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:28898771:A:C	C268W	0.987
17:28901548:A:C	F105L	0.983
17:28901548:A:T	F105L	0.983
17:28901550:A:G	F105L	0.983
17:28898730:A:G	F282S	0.982
17:28898654:G:C	S307R	0.979
17:28898654:G:T	S307R	0.979
17:28898656:T:G	S307R	0.979
17:28898772:C:T	C268Y	0.977
17:28902823:A:T	V41D	0.977
17:28898729:A:C	F282L	0.974
17:28898729:A:T	F282L	0.974
17:28898731:A:G	F282L	0.974
17:28902671:G:T	A53E	0.973
17:28902672:C:G	A53P	0.973
17:28902829:G:T	A39D	0.972
17:28898769:G:T	A269D	0.967
17:28898773:A:G	C268R	0.967
17:28902683:C:T	G49E	0.965
17:28901504:A:G	I120T	0.964
17:28902683:C:A	G49V	0.963
17:28902632:G:T	A66D	0.961
17:28900992:G:T	P227Q	0.960
17:28901231:A:C	F147L	0.960
17:28901231:A:T	F147L	0.960
17:28901233:A:G	F147L	0.960
17:28901582:A:C	L94W	0.960
17:28898892:C:T	G228E	0.959
17:28898730:A:C	F282C	0.958
17:28902701:C:T	G43D	0.958

dbSNP variants (sampled 300 via entrez): RS1000197598 (17:28897409 G>A,T), RS1000399316 (17:28900578 C>A), RS1000781749 (17:28904677 T>A), RS1001747134 (17:28901101 G>A), RS1002158520 (17:28900808 C>T), RS1002949638 (17:28902477 C>A,G,T), RS1002980616 (17:28902183 C>A), RS1003144896 (17:28902407 GC>G), RS1004097605 (17:28899658 A>G), RS1004719194 (17:28899985 C>A,T), RS1004808452 (17:28904234 T>C), RS1005998918 (17:28901304 G>A), RS1006823940 (17:28901374 T>A,C,G), RS1007430824 (17:28902037 C>A,G,T), RS1007613799 (17:28901799 G>A)

Disease associations

OMIM: gene MIM:616157 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression	2
Estradiol	affects cotreatment, decreases expression	2
Valproic Acid	affects expression, decreases methylation, increases expression	2
Cyclosporine	increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
abrine	decreases expression	1
bisphenol S	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Lead	affects expression	1
NADP	affects binding, increases activity	1
Quercetin	increases expression	1
Rotenone	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Tunicamycin	increases expression	1
Urethane	decreases expression	1
Aflatoxin B1	increases expression	1
Cadmium Chloride	decreases expression	1
Thapsigargin	increases expression	1
Copper Sulfate	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1Q4	Abcam HeLa DHRS13 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.